BOT 4.05% 38.5¢ botanix pharmaceuticals ltd

LEAD PRODUCT: BTX 1503 (MODERATE TO SEVERE ACNE) - Phase 2 clinical trial, page-19

  1. 1,400 Posts.
    lightbulb Created with Sketch. 560
    Correct, but then it begs the question: would they want resolution 7 to be taken off the agenda?
    Say that results are coming in and as these are being reviewed it becomes apparent -to Vince & co. - that BOT's MC is not gonna stay under the $300m limits post announcement, it may indeed be expected to approach or surpass OPT's MC .
    What should Vince do? Renounce to the comfort of having 10% extra capacity to raise for phase 3 (and therefore be in a better bargaining position with possible suitors) or miss it for a mere 48hs (say the TH is Tuesday with announcement by Friday)??

    Last edited by aburbe: 17/10/19
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.